# Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

> **NCT07428499** · PHASE3 · RECRUITING · sponsor: **ADARx Pharmaceuticals, Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Hereditary Angioedema (HAE)
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2
- HAE

## Interventions

- **DRUG:** ADX-324 Dose Level 1
- **DRUG:** ADX-324 Dose Level 2

## Key facts

- **NCT ID:** NCT07428499
- **Lead sponsor:** ADARx Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-02
- **Primary completion:** 2030-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07428499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07428499, "Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07428499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*